



November 1, 2014 • Volume 20 • Number 21

**Highlights of This Issue 5341****SPECIAL FEATURES****CCR Translations**

- 5343** Hormone Whodunit: Clues for Solving the Case of Intratumor Androgen Production  
Karen E. Knudsen  
*See related article, p. 5547*
- 5346** Matching Wits with Melanoma Brain Metastases: From Biology to Therapeutics  
Hussein Tawbi  
*See related article, p. 5537*

**CCR New Strategies**

- 5349** New Strategies in Advanced Cervical Cancer: From Angiogenesis Blockade to Immunotherapy  
Krishnansu S. Tewari and Bradley J. Monk

**CCR Perspectives in Drug Approval**

- 5359** First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer  
Laleh Amiri-Kordestani, Suparna Wedam, Lijun Zhang, Shenghui Tang, Amy Tilley, Amna Ibrahim, Robert Justice, Richard Pazdur, and Patricia Cortazar

**CCR Drug Updates**

- 5365** Ibrutinib for the Treatment of Mantle Cell Lymphoma  
Alex F. Herrera and Eric D. Jacobsen

**Molecular Pathways**

- 5372** Molecular Pathways: Epigenetic Modulation of Wnt–Glycogen Synthase Kinase-3 Signaling to Target Human Cancer Stem Cells  
Yannick D. Benoit, Borhane Guezguez, Allison L. Boyd, and Mickie Bhatia

- 5379** Molecular Pathways: Intercellular PTEN and the Potential of PTEN Restoration Therapy  
Benjamin D. Hopkins and Ramon E. Parsons

CME

**Review**

- 5384** Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence  
Andreas R. de Biasi, Jonathan Villena-Vargas, and Prasad S. Adusumilli

**CANCER THERAPY: CLINICAL**

- 5392** A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study  
Anish Thomas, Arun Rajan, Eva Szabo, Yusuke Tomita, Corey A. Carter, Barbara Scepora, Ariel Lopez-Chavez, Min-Jung Lee, Christophe E. Redon, Ari Frosch, Cody J. Peer, Yuanbin Chen, Richard Piekarz, Seth M. Steinberg, Jane B. Trepel, William D. Figg, David S. Schrupp, and Giuseppe Giaccone

**PERSONALIZED MEDICINE AND IMAGING**

- 5403** Qualification of a Noninvasive Magnetic Resonance Imaging Biomarker to Assess Tumor Oxygenation  
Florence Colliez, Marie-Aline Neveu, Julie Magat, Thanh Trang Cao Pham, Bernard Gallez, and Bénédicte F. Jordan

**CANCER THERAPY: PRECLINICAL**

- 5412** mTOR Inhibitors Induce Cell-Cycle Arrest and Inhibit Tumor Growth in Epstein–Barr Virus–Associated T and Natural Killer Cell Lymphoma Cells  
Jun-ichi Kawada, Yoshinori Ito, Seiko Iwata, Michio Suzuki, Yoshihiko Kawano, Tetsuhiro Kanazawa, Mohammed Nure Alam Siddiquey, and Hiroshi Kimura

# Table of Contents

**5423** Targeting the Oncogenic MUC1-C Protein Inhibits Mutant EGFR-Mediated Signaling and Survival in Non-Small Cell Lung Cancer Cells  
Akriti Kharbanda, Hasan Rajabi, Caining Jin, Jeremy Tchaicha, Eiki Kikuchi, Kwok-Kin Wong, and Donald Kufe

**5435** Deoxycytidine Kinase Expression Underpins Response to Gemcitabine in Bladder Cancer  
Martin Kerr, Helen E. Scott, Blaz Groselj, Michael R.L. Stratford, Katalin Karaszi, Naomi L. Sharma, and Anne E. Kiltie

**5446** Inhibition of *NANOG/NANOGP8* Downregulates MCL-1 in Colorectal Cancer Cells and Enhances the Therapeutic Efficacy of BH3 Mimetics  
Abid R. Mattoo, Jingyu Zhang, Luis A. Espinoza, and J. Milburn Jessup

**5456** Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8<sup>+</sup> T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFN $\gamma$   
Ruey-Shyang Soong, Liwen Song, Janson Trieu, Jayne Knoff, Liangmei He, Ya-Chea Tsai, Warner Huh, Yung-Nien Chang, Wen-Fang Cheng, Richard B.S. Roden, T.-C. Wu, Cornelia L. Trimble, and Chien-Fu Hung

**5468** The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness  
Chellappagounder Thangavel, Ettickan Boopathi, Steve Ciment, Yi Liu, Raymond O' Neill, Ankur Sharma, Steve B. McMahon, Hestia Mellert, Sankar Addya, Adam Ertel, Ruth Birbe, Paolo Fortina, Adam P. Dicker, Karen E. Knudsen, and Robert B. Den

**5483** Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R  
Ellen Weisberg, Atsushi Nonami, Zhao Chen, Erik Nelson, Yongfei Chen, Feiyang Liu, HaeYeon Cho, Jianming Zhang, Martin Sattler, Constantine Mitsiades, Kwok-Kin Wong, Qingsong Liu, Nathanael S. Gray, and James D. Griffin

**5496** Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer  
Naïke Casagrande, Marta Celegato, Cinzia Borghese, Maurizio Mongiat, Alfonso Colombatti, and Donatella Aldinucci

## BIOLOGY OF HUMAN TUMORS

**5507** Deficient Cutaneous Antibacterial Competence in Cutaneous T-Cell Lymphomas: Role of Th2-Mediated Biased Th17 Function  
Kerstin Wolk, Hiroshi Mitsui, Katrin Witte, Sylke Gellrich, Nicholas Gulati, Daniel Humme, Ellen Witte, Melanie Gonsior, Marc Beyer, Marshall E. Kadin, Hans-Dieter Volk, James G. Krueger, Wolfram Sterry, and Robert Sabat

**5517** Activating *FGFR2-RAS-BRAF* Mutations in Ameloblastoma  
Noah A. Brown, Delphine Rolland, Jonathan B. McHugh, Helmut C. Weigel, Lili Zhao, Megan S. Lim, Kojo S.J. Elenitoba-Johnson, and Bryan L. Betz

**5527** Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with *BRAF*<sup>V600</sup> Mutations  
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael Tetzlaff, Russell Broadbuss, Denai Milton, Patricia Fox, Roland Bassett, Patrick Hwu, Jeffrey E. Gershenwald, Alexander J. Lazar, and Michael A. Davies

**5537** Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target  
Guo Chen, Nitin Chakravarti, Kimberly Aardalen, Alexander J. Lazar, Michael T. Tetzlaff, Bradley Wubbenhorst, Sang-Bae Kim, Scott Kopetz, Alicia A. Ledoux, Y.N. Vashisht Gopal, Cristiano Goncalves Pereira, Wanleng Deng, Ju-Seog Lee, Katherine L. Nathanson, Kenneth D. Aldape, Victor G. Prieto, Darrin Stuart, and Michael A. Davies  
*See related commentary, p. 5346*



# Table of Contents

**5547** **Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer**



Matthew Fankhauser, Yuen Tan, Geoff Macintyre, Izhak Haviv, Matthew K.H. Hong, Anne Nguyen, John S. Pedersen, Anthony J. Costello, Christopher M. Hovens, and Niall M. Corcoran  
*See related commentary, p. 5343*

**5558** **Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response**

Peiwen Kuo, Scott V. Bratman, David B. Shultz, Rie von Eyben, Cato Chan, Ziwei Wang, Carmen Say, Aparna Gupta, Bill W. Loo Jr, Amato J. Giaccia, Albert C. Koong, Maximilian Diehn, and Quynh-Thu Le



AC icon indicates Author Choice



CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

The cover shows immunohistochemical sections of xenografts derived from gemcitabine-sensitive CAL29 bladder cancer cells. Sections were stained for Dck, and nuclear positivity was quantified using Aperio scanscope software, using the Nuclear v9 algorithm. For details, see the article by Kerr and colleagues on page 5435 of this issue.

